Natasha Persaud

TL;DR: The replication-defective adenovirus is a promising vaccine vector for development of an HIV-1 vaccine and elicited by a replication-incompetent Ad5 vector, used either alone or as a booster inoculation after priming with a DNA vector.

TL;DR: Results are suggestive of an immunization strategy for humans that is centered on use of the adenovirus vector and in which existing adenavirus immunity may be overcome by combined immunization with adjuvanted DNA and adenvirus vector boosting.

TL;DR: Over overlapping 15 amino acid peptide mixes may facilitate the analysis of antigen-specific CD4+ and CD8+ T-cell responses by cytokine flow cytometry, using clinical specimens that include shipped blood or cryopreserved PBMC.

TL;DR: It is suggested that the high levels of ELISpot responses in chronically infected subjects were reflective of their persistent viral infection, and a positive correlation between host viral loads and ELIS Pot responses of HIV Gag and Pol in untreated subjects was demonstrated.

TL;DR: The statistical criteria established by these analyses allow for the accurate detection and comparison of positive responses and conclude that the ICS assay is sufficiently robust for use in HIV-specific vaccine trials.